LDS/Medical Tests/Mismatch Repair (MMR) Protein, Immunohistochemistry

Mismatch Repair (MMR) Protein, Immunohistochemistry

DNA mismatch repair (MMR) proteins play a critical role in maintaining genomic stability by identifying and correcting base-pairing errors that occur during DNA replication. Defects in this repair system referred to as deficient MMR (dMMR) result in the accumulation of mutations and increased genomic instability, predisposing to carcinogenesis.

The key MMR proteins include MLH1, MSH2, MSH6, and PMS2. Loss or dysfunction of one or more of these proteins can arise sporadically or through germline mutations, particularly in Lynch syndrome, the most common hereditary colorectal cancer syndrome. Individuals with Lynch syndrome are at elevated risk for colorectal, endometrial, ovarian, gastric, and other malignancies.

Immunohistochemistry (IHC) is a validated, cost-effective, and widely accessible technique for assessing MMR protein expression in tumor tissues. It serves as a reliable surrogate for microsatellite instability (MSI) molecular testing. Multiple studies, including large meta-analyses, have confirmed the high diagnostic accuracy of MMR IHC in identifying dMMR tumors, with reported sensitivity of 96%, specificity of 95%, and AUC of 0.988.

Detection of dMMR tumors has significant clinical implications. These tumors often display poor response to certain chemotherapies but enhanced sensitivity to immune checkpoint inhibitors (e.g., pembrolizumab, dostarlimab). Thus, IHC-based identification of dMMR not only assists in screening for Lynch syndrome but also plays an important role in therapeutic decision-making and prognostic assessment.

  • As an aid in the diagnosis of colorectal cancer associated with Lynch Syndrome (mismatch repeat mutations)
  • As an aid in the diagnosis of endometrial cancer associated with Lynch Syndrome (mismatch repeat mutations)
  • Provides prognostic and therapeutic insights for immunotherapy response and chemotherapy selection
Result IHC Findings Interpretation
Proficient MMR (pMMR) Nuclear staining present for all four MMR proteins (MLH1, MSH2, MSH6, PMS2) in tumor cells; internal positive control staining (stromal or inflammatory cells) present Normal MMR function
Deficient MMR (dMMR) Loss of nuclear staining in tumor cells for one or more MMR proteins, with preserved staining in internal controls Suggests MMR deficiency; supports MSI-high phenotype and possible Lynch syndrome

 

Proficient MMR (normal expression of MLH1, MSH2, MSH6, PMS2)

Immunohistochemistry (IHC) using monoclonal antibodies for MLH1, MSH2, MSH6, and PMS2.

Formalin-fixed paraffin embedded (FFPE) tissue.

Stability

FFPE specimens are stable at room temperature for longer. 

Colon biopsy, Lynch syndrome Multigene panel, MSI HNPCC, CBC, PMS2 gene mutation analysis, comprehensive metabolic panel, BRAF gene mutation analysis, SMAD4 germline mutation analysis, Edendx.
3 to 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login